Eli Lilly prepares to present key clinical trial updates for its investigational oncology candidates, including sofetabart mipitecan and olomorasib, at the upcoming ESMO Congress.
Eli Lilly is set to present significant clinical data at the upcoming ESMO Congress, focusing on its oncology pipeline. The presentations include initial Phase 1 results for the FRα-targeting ADC sofetabart mipitecan in ovarian cancer and updated first-line data for the KRAS G12C-mutant NSCLC therapy, olomorasib.
The data focuses on Phase 1 results for the investigational FRα-targeting ADC in patients with platinum-sensitive ovarian cancer.
The updated first-line data for olomorasib targets KRAS G12C-mutant non-small cell lung cancer (NSCLC).
Eli Lilly will present new clinical data for its investigational oncology portfolio at the upcoming ESMO Congress. The company plans to showcase Phase 1 results for its FRα-targeting ADC, sofetabart mipitecan, alongside updated first-line data for the KRAS G12C-mutant NSCLC therapy, olomorasib.
Eli Lilly is presenting initial Phase 1 data for its FRα-targeting ADC, sofetabart mipitecan, and updated first-line data for its KRAS G12C-mutant NSCLC therapy, olomorasib.